Full-year 2024 guidance raised as net sales expected to grow low double-digit, up from “high single to low double-digit,” and core operating income expected to grow high teens, up from “mid to high teens.”
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis Reports Strong Q3 Growth and Raises Guidance
- Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler
- Monte Rosa announces global license agreement with Novartis
- Novartis presents 12-month data from the Phase III APPEAR-C3G study
- NVS Earnings this Week: How Will it Perform?